Shares of Moderna Inc. rose 0.5% in premarket trading Monday, after the biotechnology company said it had submitted for conditional market approval (CMA) with the European Medicines Agency (EMA) for its COVID-19 vaccine in adolescents, ages 12 to less than 18. In May, the company said the Phase 2/3 study of its vaccine in adolescents met its primary immunogenicity endpoint. “We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection i
Moderna submits for marketing approval of COVID-19 vaccine in adolescents in Europe
2021-06-07T12:42:34-04:00June 7th, 2021|
Related Posts
-
Dow Hits 40,000: On The Road To 1,00,000?
May 17th, 2024 -
Beware When Choosing Assisted Living For An Aging Parent
May 16th, 2024